doi:https://doi.org/

References:

Hart R.G., Diener H.-C., Coutts S.B., et al. Embolic strokes of undetermined source: the case for a new clinical construct. Lancet Neurol 2014;13:429—438.
Li L., Yiin G.S., Geraghty O.C., et al. Incidence, outcome, risk factors, and long-term prognosis of cryptogenic transient ischaemic attack and ischaemic stroke: a population-based study. Lancet Neurol 2015;14:903—913.
Saver J.L. Cryptogenic stroke. N Engl J Med 2016;374:2065—2074.
Ruff C.T., Giugliano R.P., Braunwald E., et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarn in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014;383:955—962.
Hart R.G., Pearce L.A., Aguilar M.I. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007;146:857—867.
Hart R.G., Sharma M., Mundl H., et al. Rivaroxaban for secondary stroke prevention in patients with embolic strokes of undetermined source: design of the NAVIGATE ESUS randomized trial. Eur Stroke J 2016;1:146—154.
Hart R.G., Tonarelli S.B., Pearce L.A. Avoiding central nervous system bleeding during antithrombotic therapy: recent data and ideas. Stroke 2005;36: 1588—1593.
Sanna T., Diener H.C., Passman R.S., et al. Cryptogenic stroke and underlying atrial fibrillation. N Engl J Med 2014;370:2478—86.
Hankey G.J., Patel M.R., Stevens S.R., et al. Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF. Lancet Neurol 2012;11: 315—322.
Hori M., Matsumoto M., Tanahashi N., et al. Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation — the J-ROCKET AF study. Circ J 2012;76:2104—2111.
López-López J.A., Sterne J.A.C., Thom H.H.Z., et al. Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis. BMJ 2017;359:j5058.7u
Mas J.-L., Derumeaux G., Guillon B., et al. Patent foramen ovale closure or anticoagulation vs antiplatelets after stroke. N Engl J Med 2017;377:1011—1021.
Saver J.L., Carroll J.D., Thaler D.E., et al. Long-term outcomes of patent foramen ovale closure or medical therapy after stroke. N Engl J Med 2017;377: 1022—1032.
Søndergaard L., Kasner S.E., Rhodes J.F., et al. Patent foramen ovale closure or antiplatelet therapy for cryptogenic stroke. N Engl J Med 2017;377:1033—1042.
Stampfuss J., Kubitza D., Becka M., Mueck W. The effect of food on the absorption and pharmacokinetics of rivaroxaban. Int J Clin Pharmacol Ther 2013;51:549—561.
Diener H.C., Easton J.D., Granger C.B., et al. Design of Randomized, double-blind, Evaluation in secondary Stroke Prevention comparing the EfficaCy and safety of the oral Thrombin inhibitor dabigatran etexilate vs. acetylsalicylic acid in patients with Embolic Stroke of Undetermined Source (RE-SPECT ESUS). Int J Stroke 2015;10:1309—1312.
Geisler T., Poli S., Meisner C., et al. Apixaban for treatment of embolic stroke of undetermined source (ATTICUS randomized trial): rationale and study design. Int J Stroke 2017;12:985—990.